We’ve completed more than 4,000 consecutive isolated mitral valve repairs without a perioperative death. Our team shares cultural and technical factors behind that achievement as well as persistent repair durability.
The new NIH-funded multicenter investigation will help determine which therapy — MitraClip or surgery — is better in which patient types.
An underrecognized form of functional mitral regurgitation of atrial origin demands heightened attention due to higher risks of death and hospitalization for heart failure and lower intervention rates.
Three of our valve disease experts reflect on notable changes and developments related to mitral valve disease in the new guideline update.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Repair is feasible in over 95% cases of mitral valve prolapse and yields better outcomes than replacement, provided that these best practices are followed.
Expanded use of minimally invasive mitral valve surgery will be the No. 2 most influential medical innovation for 2020, predict experts at Cleveland Clinic.
It’s increasingly clear that there’s no good reason to delay surgical repair in patients with primary mitral valve disease and severe regurgitation. Two experts share perspectives about what that means in practice.
Ischemic mitral regurgitation is extremely difficult to manage. That’s why Dr. Deborah Kwon is intent on identifying imaging-based predictors of progression to enable earlier and wiser intervention.
This newly approved percutaneous therapy offers a minimally invasive option for mitral regurgitation patients at high risk from surgery. Ongoing studies aim to better define just which patients benefit.